Recent drug discovery developments in the field of small molecule targeted agents have led
to much interest in combining these with radiotherapy. There are good preclinical data to …

This paper explores historical and current roles of pharmaceutical industry sponsorship of
clinical trials testing radiation therapy combinations with molecularly targeted agents and …

The field of nuclear medicine has had decades of experience in the use of radionuclides for
the targeted therapy of disease. The routine use of iodine-131 for the treatment of thyroid …

Radiotherapy plays an integral role in cancer treatment. Approximately 60% of cancer
patients will receive radiotherapy at some point in their treatment. A major improvement in …

Today, combined radiochemotherapy is firmly established in clinical practice for a wide
spectrum of tumours. Randomized trials have shown that in many cases, this strategy may …

The development of molecular targeted therapeutics in oncology builds on many years of
scientific investigation into the cellular mechanics of malignant transformation and …

Background and purpose Targeted drugs have augmented the cancer treatment
armamentarium. Based on the molecular specificity, it was initially believed that these drugs …

The combination of molecular-targeted agents with irradiation is a highly promising avenue
for cancer research and patient care. Molecular-targeted agents are in themselves not …

Chemoradiation is the standard therapy for the majority of inoperable, locally advanced
cancers. Although there is a need to improve chemoradiation efficacy, normal-tissue toxicity …

In the era of precision medicine, radiation medicine is currently focused on the precise
delivery of highly conformal radiation treatments. However, the tremendous developments in …